Patient-reported outcomes 12 years after localized prostate cancer treatment
BACKGROUND<br> Long-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer. <br><br> METHODS<br> Patient-reported outcomes of 1643 randomly assigned participants in the ProtecT (Prostate Testing for Cancer and Treatment) trial we...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
NEJM Group
2023
|
| _version_ | 1826310806187278336 |
|---|---|
| author | Donovan, JL Hamdy, FC Lane, JA Young, GJ Metcalfe, C Walsh, EI Davis, M Steuart-Feilding, T Blazeby, JM Avery, KNL Martin, RM Bollina, P Doble, A Doherty, A Gillatt, D Gnanapragasam, V Hughes, O Kockelbergh, R Kynaston, H Paul, A Paez, E Powell, P Rosario, DJ Rowe, E Mason, M Catto, JWF Peters, TJ Wade, J Turner, EL Williams, NJ Oxley, J Staffurth, J Bryant, RJ Neal, DE |
| author_facet | Donovan, JL Hamdy, FC Lane, JA Young, GJ Metcalfe, C Walsh, EI Davis, M Steuart-Feilding, T Blazeby, JM Avery, KNL Martin, RM Bollina, P Doble, A Doherty, A Gillatt, D Gnanapragasam, V Hughes, O Kockelbergh, R Kynaston, H Paul, A Paez, E Powell, P Rosario, DJ Rowe, E Mason, M Catto, JWF Peters, TJ Wade, J Turner, EL Williams, NJ Oxley, J Staffurth, J Bryant, RJ Neal, DE |
| author_sort | Donovan, JL |
| collection | OXFORD |
| description | BACKGROUND<br>
Long-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer.
<br><br>
METHODS<br>
Patient-reported outcomes of 1643 randomly assigned participants in the ProtecT (Prostate Testing for Cancer and Treatment) trial were evaluated to assess the functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring. This article focuses on the outcomes of the randomly assigned participants from 7 to 12 years using mixed effects linear and logistic models.
<br><br>
RESULTS<br>
Response rates exceeded 80% for most measures. Among the randomized groups over 7 to 12 years, generic quality-of-life scores were similar. Among those in the prostatectomy group, urinary leakage requiring pads occurred in 18 to 24% of patients over 7 to 12 years, compared with 9 to 11% in the active monitoring group and 3 to 8% in the radiotherapy group. In the prostatectomy group, 18% reported erections sufficient for intercourse at 7 years, compared with 30% in the active monitoring and 27% in the radiotherapy groups; all converged to low levels of potency by year 12. Nocturia (voiding at least twice per night) occurred in 34% in the prostatectomy group compared with 48% in the radiotherapy group and 47% in the active monitoring group at 12 years. Fecal leakage affected 12% in the radiotherapy group compared with 6% in the other groups by year 12. The active monitoring group experienced gradual age-related declines in sexual and urinary function, avoiding radical treatment effects unless they changed management.
<br><br>
CONCLUSIONS<br>
ProtecT provides robust evidence about continued impacts of treatments in the long term. These data allow patients newly diagnosed with localized prostate cancer and their clinicians to assess the trade-offs between treatment harms and benefits and enable better informed and prudent treatment decisions. (Funded by the UK National Institute for Health and Care Research Health Technology Assessment Programme projects 96/20/06 and 96/20/99; ISRCTN number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.) |
| first_indexed | 2024-03-07T07:58:58Z |
| format | Journal article |
| id | oxford-uuid:63cfe490-e091-4d90-921f-76bf98866f0b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:58:58Z |
| publishDate | 2023 |
| publisher | NEJM Group |
| record_format | dspace |
| spelling | oxford-uuid:63cfe490-e091-4d90-921f-76bf98866f0b2023-09-11T12:05:51ZPatient-reported outcomes 12 years after localized prostate cancer treatment Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:63cfe490-e091-4d90-921f-76bf98866f0bEnglishSymplectic ElementsNEJM Group2023Donovan, JLHamdy, FCLane, JAYoung, GJMetcalfe, CWalsh, EIDavis, MSteuart-Feilding, TBlazeby, JMAvery, KNLMartin, RMBollina, PDoble, ADoherty, AGillatt, DGnanapragasam, VHughes, OKockelbergh, RKynaston, HPaul, APaez, EPowell, PRosario, DJRowe, EMason, MCatto, JWFPeters, TJWade, JTurner, ELWilliams, NJOxley, JStaffurth, JBryant, RJNeal, DEBACKGROUND<br> Long-term patient-reported outcomes are needed to inform treatment decisions for localized prostate cancer. <br><br> METHODS<br> Patient-reported outcomes of 1643 randomly assigned participants in the ProtecT (Prostate Testing for Cancer and Treatment) trial were evaluated to assess the functional and quality-of-life impacts of prostatectomy, radiotherapy with neoadjuvant androgen deprivation, and active monitoring. This article focuses on the outcomes of the randomly assigned participants from 7 to 12 years using mixed effects linear and logistic models. <br><br> RESULTS<br> Response rates exceeded 80% for most measures. Among the randomized groups over 7 to 12 years, generic quality-of-life scores were similar. Among those in the prostatectomy group, urinary leakage requiring pads occurred in 18 to 24% of patients over 7 to 12 years, compared with 9 to 11% in the active monitoring group and 3 to 8% in the radiotherapy group. In the prostatectomy group, 18% reported erections sufficient for intercourse at 7 years, compared with 30% in the active monitoring and 27% in the radiotherapy groups; all converged to low levels of potency by year 12. Nocturia (voiding at least twice per night) occurred in 34% in the prostatectomy group compared with 48% in the radiotherapy group and 47% in the active monitoring group at 12 years. Fecal leakage affected 12% in the radiotherapy group compared with 6% in the other groups by year 12. The active monitoring group experienced gradual age-related declines in sexual and urinary function, avoiding radical treatment effects unless they changed management. <br><br> CONCLUSIONS<br> ProtecT provides robust evidence about continued impacts of treatments in the long term. These data allow patients newly diagnosed with localized prostate cancer and their clinicians to assess the trade-offs between treatment harms and benefits and enable better informed and prudent treatment decisions. (Funded by the UK National Institute for Health and Care Research Health Technology Assessment Programme projects 96/20/06 and 96/20/99; ISRCTN number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.) |
| spellingShingle | Donovan, JL Hamdy, FC Lane, JA Young, GJ Metcalfe, C Walsh, EI Davis, M Steuart-Feilding, T Blazeby, JM Avery, KNL Martin, RM Bollina, P Doble, A Doherty, A Gillatt, D Gnanapragasam, V Hughes, O Kockelbergh, R Kynaston, H Paul, A Paez, E Powell, P Rosario, DJ Rowe, E Mason, M Catto, JWF Peters, TJ Wade, J Turner, EL Williams, NJ Oxley, J Staffurth, J Bryant, RJ Neal, DE Patient-reported outcomes 12 years after localized prostate cancer treatment |
| title | Patient-reported outcomes 12 years after localized prostate cancer treatment
|
| title_full | Patient-reported outcomes 12 years after localized prostate cancer treatment
|
| title_fullStr | Patient-reported outcomes 12 years after localized prostate cancer treatment
|
| title_full_unstemmed | Patient-reported outcomes 12 years after localized prostate cancer treatment
|
| title_short | Patient-reported outcomes 12 years after localized prostate cancer treatment
|
| title_sort | patient reported outcomes 12 years after localized prostate cancer treatment |
| work_keys_str_mv | AT donovanjl patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT hamdyfc patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT laneja patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT younggj patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT metcalfec patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT walshei patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT davism patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT steuartfeildingt patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT blazebyjm patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT averyknl patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT martinrm patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT bollinap patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT doblea patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT dohertya patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT gillattd patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT gnanapragasamv patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT hugheso patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT kockelberghr patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT kynastonh patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT paula patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT paeze patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT powellp patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT rosariodj patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT rowee patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT masonm patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT cattojwf patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT peterstj patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT wadej patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT turnerel patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT williamsnj patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT oxleyj patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT staffurthj patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT bryantrj patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment AT nealde patientreportedoutcomes12yearsafterlocalizedprostatecancertreatment |